PRESS RELEASES

Date Title and Summary View
Toggle Summary PRO-PHARMACEUTICALS RECEIVES FINAL TRANCHE OF FUNDING FROM FEDERAL GRANT; RAISES CASH POSITION TO $8 MILLION View HTML
Toggle Summary PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE View HTML
Toggle Summary PRO-PHARMACEUTICALS ANNOUNCES SIGNIFICANT ADVANCE IN DEFINING DAVANAT®'s MECHANISM OF ACTION BASED ON EXPERIMENTS DONE AT THE UNIVERSITY OF MINNESOTA AND THE LUDWIG INSTITUTE IN BRUSSELS, BELGIUM
Studies Demonstrate DAVANAT® Binds To Galectin-1 and Galectin-3 Receptors That Control Angiogenesis and the Tumor's Ability To Evade the Immune System
View HTML
Toggle Summary THE LUDWIG INSTITUTE AND PRO-PHARMACEUTICALS COLLABORATE TO TEST DAVANAT®'s ABILITY TO ENHANCE THE FUNCTION OF ANTI-TUMOR T LYMPHOCYTES
Pro-Pharmaceuticals' DAVANAT® Targets Galectin Receptors on Cancer Cells and Removes Their Ability to Evade the Immune System
View HTML
Toggle Summary PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE View HTML
Toggle Summary Pro-Pharmaceuticals Reports Third Quarter Financial Results View HTML
Toggle Summary PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE; BRINGS TOTAL TO $4.1 MILLION OF $6.0 MILLION PRIVATE PLACEMENT View HTML
Toggle Summary PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE; BRINGS TOTAL TO $3.8 MILLION OF $6.0 MILLION PRIVATE PLACEMENT View HTML
Toggle Summary PRO-PHARMACEUTICALS TO PRESENT A CORPORATE UPDATE AT THE MAXIM GROUP GROWTH CONFERENCE View HTML
Toggle Summary PRO-PHARMACEUTICALS TO PRESENT A CORPORATE UPDATE AT THE RODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE View HTML